However, according to CAP, GLP-1RAs only showed a trend of better effects than TZDs and did not reach statistical significance.
← all excerpts
Correspondence to editorial on "Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis".
1
—
—